Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic acid cardiovascular outcomes trial in statin-intolerant patients
NL-OMON53050Phase 3Active, not recruiting
- Sponsor
- Esperion Therapeutics
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity and hypercholesterolemia comparing Bempedoic acid with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started May 2017; status: active, not recruiting.
02
Drugs
bempedoic acid
03
Conditions
cardiac morbidityhypercholesterolemia
Beyond the preview
Go deeper on NL-OMON53050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53050.